SCHEMBL10698743

SCHEMBL10698743

C1=Cc2ncccc2Oc2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TRPA1 O75762 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
POLB P06746 1/20 0.33
CASP6 P55212 1/20 0.33
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
GRM1 Q13255 1/20 0.30
ALOX5 P09917 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10716991 0.82 TRPA1 (0.42) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL6852823 0.80 CA12 (0.47) MEN1KMT2AMAPTALDH1A1KDM4E
Dibenzo[B,F]Oxepine SCHEMBL1650179 0.78 MEN1 (0.64) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL25224484 0.75 ALOX5 (0.40) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL17849602 0.74 CA12 (0.34) CA12CA1CA2CA9
SCHEMBL3261185 0.74
SCHEMBL18020275 0.73 KDM4E (0.42) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL19821014 0.69 MEN1 (0.39) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL10701435 0.67 TRPA1 (0.41) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL8105009 0.67 CA12 (0.42) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3256468-B1 TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2020-04-08 EP disclosed
US-10183917-B2 Tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-01-22 US disclosed
US-20180030003-A1 TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-02-01 US disclosed
EP-0270692-A1 ANTIARRHYTHMIC AGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 1988-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030003-A1 TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE NR1H4, SLC10A1, SLC10A2 MEN1 2860/4885KMT2A 4543/4885MAPT 177/4885
US-10183917-B2 Tricyclic compounds and uses thereof in medicine NR1H4, SLC10A1, SLC10A2 MEN1 2860/4885KMT2A 4543/4885MAPT 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.